# Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Voxilaprevir in Adults With Chronic Hepatitis C Virus Infection

> **NCT02185794** · PHASE1 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 101 (actual)

## Conditions studied

- Hepatitis C Virus Infection

## Interventions

- **DRUG:** Voxilaprevir
- **DRUG:** Placebo to match voxilaprevir
- **DRUG:** SOF/VEL

## Key facts

- **NCT ID:** NCT02185794
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-06-13
- **Primary completion:** 2014-12-22
- **Final completion:** 2015-09-28
- **Target enrollment:** 101 (ACTUAL)
- **Last updated:** 2020-09-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02185794

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02185794, "Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Voxilaprevir in Adults With Chronic Hepatitis C Virus Infection". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02185794. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*